Stroke: More trials, more answers

The Lancet Neurology

Volumn 11, Issue 1, 2012, Pages 2-3

  Rothwell, Peter M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CANDESARTAN; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; TERUTROBAN; WARFARIN; XIMELAGATRAN;

ANTICOAGULANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; LIVER TOXICITY; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STROKE; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; STROKE;

EID: 83455249891     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(11)70283-6     Document Type: Note

References (8)

1. Bousser M-G, Amarenco P, Chamorro A, et al. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011, 377:2013-2022. on behalf of the PERFORM Study Investigators.
2. Sandset EC, Bath PMW, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011, 377:741-750. on behalf of the SCAST Study Group.
3. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362:1691-1698. Executive Steering Committee on behalf of the SPORTIF III Investigators.
4. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361:1139-1151. the RE-LY Steering Committee and Investigators.
5. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891. the ROCKET AF Steering Committee for the ROCKET AF Investigators.
6. Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992. for the ARISTOTLE Committees and Investigators.
7. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011, 364:806-817. for the AVERROES Steering Committee and Investigators.
8. Chimowitz MI, Lynn MJ, Derdeyn CP, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011, 365:993-1003. for the SAMMPRIS Trial Investigators.